Company / R&D Expense
NovoCure Ltd R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$224.5M
FY2025
5-year range
$201.3M / $224.5M
FY2021-FY2025
Trend
+7.1%
vs FY2024
Sector context
#32 of 105
Health Care
What the data says
At $225M, NovoCure Ltd's r&d expense ranks #32 of 105 in the Health Care sector. R&D Expense has fluctuated over the past 10 years, ranging from $38M in FY2017 to $225M in FY2025.
Based on SEC 10-K filings.
$225M in FY2025 with a 5-year CAGR of +11.2%.
Remained stable around $225M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +2.9%
- 5-Year CAGR
- +11.2%
- 10-Year CAGR
- -
Sector benchmark
#32 of 105 in Health CareTop 30% of 105This company $224.5M Sector average $284.2M
▼
-21.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +11.2%, indicating consistent growth.
- In FY2025, r&d expense increased 7.1% year-over-year.
- Ranks #32 out of 105 companies in the Health Care sector.
- Lowest r&d expense in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score -0.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $224.5M | +7.1% |
| FY2024 | $209.6M | -6.0% |
| FY2023 | $223.1M | +8.2% |
| FY2022 | $206.1M | +2.4% |
| FY2021 | $201.3M | +52.5% |
| FY2020 | $132.0M | +67.1% |
| FY2019 | $79.0M | +56.2% |
| FY2018 | $50.6M | +32.7% |
| FY2017 | $38.1M | -8.1% |
| FY2016 | $41.5M | -5.2% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026